Related Experiment Videos
Glycosylated haemoglobin concentrations in newly diagnosed diabetics before and during treatment
Insights
Glycosylated hemoglobin (HbA1) levels in diabetics reflect blood glucose control over 1-2 months. Treatment improved HbA1, with duration of high blood sugar also impacting levels.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Clinical Chemistry
Background:
- Glycosylated hemoglobin (HbA1) is a key indicator of long-term glycemic control in diabetes mellitus.
- Understanding factors influencing HbA1 levels, such as treatment modality and symptom duration, is crucial for effective diabetes management.
Purpose of the Study:
- To investigate the relationship between different diabetes treatments (chlorpropamide, insulin, diet alone) and changes in HbA1 concentrations.
- To assess the influence of symptom duration and plasma glucose levels on HbA1 at diagnosis and during treatment.
Main Methods:
- Measurement of total glycosylated haemoglobins (HbA1) in 40 diabetic patients at diagnosis and monthly intervals post-treatment initiation.
- Comparison of HbA1 and plasma glucose levels across treatment groups (chlorpropamide, insulin, diet alone) and over a two-month period.
Main Results:
- Patients treated with chlorpropamide had higher initial HbA1 and longer symptom duration than those on insulin, despite similar plasma glucose levels.
- Diet-alone group showed lower initial HbA1 and plasma glucose, with most patients asymptomatic.
- All treatments effectively reduced symptoms and plasma glucose, leading to a significant decrease in HbA1 over two months, with no significant inter-group differences by month two.
Conclusions:
- HbA1 concentration serves as a reliable marker for glycemic control over the preceding one to two months.
- Both the absolute blood glucose concentration and the duration of hyperglycemia appear to be significant determinants of HbA1 levels in diabetic patients.
Abstract:
Concentrations of total glycosylated haemoglobins (Hb A1) were measured in 40 diabetics at diagnosis and at monthly intervals after treatment with chlorpropamide, insulin, or diet alone was begun. The mean Hb A1 concentration at presentation in 16 patients treated with chlorpropamide was significantly higher than that in 12 patients treated with insulin, and the duration of glycaemic symptoms was much longer in the chlorpropamide-treated group. In contrast, the mean plasma glucose concentration was similar in both groups. The mean concentrations of Hb A1 and plasma glucose at diagnosis in the 12 patients treated by diet alone were lower than those in the other two groups, and most of these patients were free of symptoms. Treatment quickly relieved symptoms and lowered plasma glucose in all patients. The Hb A1 concentration fell significantly with treatment such that after two months there was no significant difference between the three groups, although results remained above the normal range. These findings support the theory that the Hb A1 concentration reflects the blood glucose control over the previous one to two months and suggest that the duration of hyperglycaemia may be important in determining the Hb A1 concentration as well as the absolute blood glucose concentration.